Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-DOCK8 antibody
- Development stage
- Preclinical
- Lead developer
- Institute for Rheumatic Diseases
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Parenteral
01
Overview
The anti-DOCK8 antibody is an experimental monoclonal antibody designed to target Dedicator of cytokinesis 8 (DOCK8), a guanine nucleotide exchange factor. Research indicates that DOCK8 is expressed on the surface of a specific subset of pathogenic T follicular helper (Tfh) cells in patients with systemic lupus erythematosus (SLE). These DOCK8-positive Tfh cells are believed to drive the production of autoantibodies and the development of lupus lesions. In preclinical studies, treatment with anti-DOCK8 antibodies has demonstrated the ability to reverse SLE-like symptoms and reduce autoantibody levels in mouse models, suggesting its potential as a targeted immunotherapy for autoimmune diseases.
- Other names
- anti-DOCK8 monoclonal antibodyanti-DOCK-8 monoclonal antibodyanti-DOCK 8 monoclonal antibodyDOCK8 antibodyDOCK-8 antibodyDOCK 8 antibody
02
Targets
DOCK8 (Dedicator of cytokinesis protein 8)
Beyond the preview
Go deeper on anti-DOCK8 antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-DOCK8 antibody.